Stock Price & Volume | Full Chart
30-Day Implied Volatility | IV30 Full Chart
No headlines found.
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Business Wire (Thu, 1-Jun 9:04 AM ET)
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Business Wire (Wed, 24-May 9:00 PM ET)
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals, Inc. (ACAD) and Encourages Long-Term ACAD Investors to Contact the Firm
Globe Newswire (Wed, 24-May 8:00 AM ET)
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
Business Wire (Mon, 8-May 4:05 PM ET)
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 5-May 4:04 PM ET)
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire (Tue, 2-May 9:04 AM ET)
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
Business Wire (Tue, 25-Apr 9:04 AM ET)
Acadia Pharmaceuticals to Present DAYBUE (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
Business Wire (Thu, 20-Apr 9:04 AM ET)
Acadia Pharmaceuticals Announces DAYBUE (trofinetide) is Now Available for the Treatment of Rett Syndrome
Business Wire (Mon, 17-Apr 9:04 AM ET)
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Business Wire (Tue, 11-Apr 9:04 AM ET)
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Acadia Pharmaceuticals trades on the NASDAQ stock market under the symbol ACAD.
As of June 2, 2023, ACAD stock price climbed to $24.61 with 992,746 million shares trading.
ACAD has a beta of 0.13, meaning it tends to be less sensitive to market movements. ACAD has a correlation of 0.00 to the broad based SPY ETF.
ACAD has a market cap of $3.94 billion. This is considered a Mid Cap stock.
Last quarter Acadia Pharmaceuticals reported $118 million in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.06.
In the last 3 years, ACAD stock traded as high as $58.72 and as low as $12.24.
The top ETF exchange traded funds that ACAD belongs to (by Net Assets): VTI, VB, XBI, IWM, FBT.
ACAD has outperformed the market in the last year with a return of +51.8%, while the SPY ETF gained +4.1%. In the last 3 month period, ACAD beat the market returning +21.3%, while SPY returned +7.9%. However, in the most recent 2 weeks ACAD has underperformed the stock market by returning +1.2%, while SPY returned +2.2%.
ACAD support price is $23.18 and resistance is $24.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACAD stock will trade within this expected range on the day.